Article Text

Download PDFPDF
Original research
Functional annotation with expression validation identifies novel metastasis-relevant genes from post-GWAS risk loci in sporadic colorectal carcinomas
  1. Lai Fun Thean1,
  2. Michelle Wong1,
  3. Michelle Lo1,
  4. Iain Tan2,
  5. Evelyn Wong2,
  6. Fei Gao3,4,
  7. Emile Tan1,
  8. Choong Leong Tang1,
  9. Peh Yean Cheah1,4,5
  1. 1 Department of Colorectal Surgery, Singapore General Hospital, Singapore
  2. 2 Division of Medical Oncology, National Cancer Centre Singapore, Singapore
  3. 3 National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore
  4. 4 Duke-NUS Medical School, National University of Singapore, Singapore
  5. 5 Saw Swee Hock School of Public Health, National University of Singapore, Singapore
  1. Correspondence to Dr Peh Yean Cheah, Colorectal Surgery, Singapore General Hospital, Singapore, Singapore; cheah.peh.yean{at}sgh.com.sg

Abstract

Background Colorectal cancer (CRC) is the third highest incidence cancer and is the leading cause of cancer mortality worldwide. Metastasis to distal organ is the major cause of cancer mortality. However, the underlying genetic factors are unclear. This study aimed to identify metastasis-relevant genes and pathways for better management of metastasis-prone patients.

Methods A case-case genome-wide association study comprising 2677 sporadic Chinese CRC cases (1282 metastasis-positive vs 1395 metastasis-negative) was performed using the Human SNP6 microarray platform and analysed with the correlation/trend test based on the additive model. SNP variants with association testing −log10 p value ≥5 were imported into Functional Mapping and Annotation (FUMA) for functional annotation.

Results Glycolysis was uncovered as the top hallmark gene set. Transcripts from two of the five genes profiled, hematopoietic substrate 1 associated protein X 1 (HAX1) and hyaluronan-mediatedmotility receptor (HMMR), were significantly upregulated in the metastasis-positive tumours. In contrast to disease-risk variants, HAX1 appeared to act synergistically with HMMR in significantly impacting metastasis-free survival. Examining the subtype datasets with FUMA and Ingenuity Pathway Analysis (IPA) identified distinct pathways demonstrating sexual dimorphism in CRC metastasis.

Conclusions Combining genome-wide association testing with in silico functional annotation and wet-bench validation identified metastasis-relevant genes that could serve as features to develop subtype-specific metastasis-risk signatures for tailored management of patients with stage I-III CRC.

  • Gastroenterology
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Genetic Variation
  • Gene Expression

Data availability statement

Data are available upon reasonable request. Supplementary data are attached in additional files. The other datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Data are available upon reasonable request. Supplementary data are attached in additional files. The other datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

View Full Text

Footnotes

  • Contributors Conceptualisation: IT and PYC. Data curation: LFT, MW and ML. Formal analysis: LFT, FG and PYC. Funding acquisition: PYC. Investigation: LFT, MW and ML. Methodology: LFT and PYC. Project administration: LFT, ML and PYC. Resources: IT, EW, ET and CLT. Supervision: PYC. Validation: LFT, MW and ML. Writing—original draft: PYC. Writing—review and editing: LFT and PYC; guarantor: PYC.

  • Funding This research was funded by in part by a Singapore National Medical Research Council grant (NMRC/OFIRG/0004/2016) to PYC.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.